ENHANCE Study – Optimization of intra-tumour illumination and changes in patient population

Posted on Mar 5, 2013

Oslo, 25 February 2013 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has decided how to optimize the treatment procedure for intra-tumour illumination in the ENHANCE study. The company has also decided to modify the inclusion/exclusion criteria to broaden the patient population and to achieve a more rapid patient inclusion. Inclusion […]